Lu Xu

No ORCID on file · 2 papers in corpus · active 2018-2026

Study types

  • other 1
  • review 1

Condition tags

  • endometriosis 2
  • adenomyosis 1
other 2026
FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis
Journal of controlled release : official journal of the Controlled Release Society ·doi:10.1016/j.jconrel.2026.115007

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety of FGFR2 inhibitors have exhibited remarkable…

review 2018
Catechol-O-methyltransferase 158G/A polymorphism and endometriosis/adenomyosis susceptibility: A meta-analysis in the Chinese population
Journal of cancer research and therapeutics ·doi:10.4103/0973-1482.188439

PURPOSE: An association between catechol-O-methyltransferase (COMT) 158G/A polymorphism and endometriosis/adenomyosis susceptibility has been reported in the previous studies, but the results were inconsistent. This study was conducted to e…